During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen ...

Chimeric antigen receptor T cell therapy is a revolutionary approach that is a new pillar in the treatment of cancer. CAR T cell therapy has produced remarkable results in hematological malignancies; ...

Solid tumours are often heterogeneous, they contain a diverse range of cancer cells with varying characteristics ...

Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T ...

T-cell therapy has increased rapidly, the clinical benefit seen with these products comes at a cost for patients who experience toxicities related to the induction of a powerful immune response. The ...

For more information, please visit www.autolus.com About obe-cel (AUTO1) Obecabtagene autoleucel (obe-cel) is a B-lymphocyte antigen CD19 (CD19) chimeric antigen receptor (CAR) T cell investigational ...

The therapy is currently in Phase I/Ib clinical development for patients with relapsed/refractory multiple myeloma.

“I am honored to have been named a K12 scholar,” says McNerney. “To me, this represents Northwestern’s commitment to my ...

Cell and gene therapy: Dr. Jeff Hersh examines 25 years of technological advances In general, earlier stage cancers have ...

The principal goal of therapies for multiple myeloma, which remains incurable, is to extend progression-free survival, but challenges remain bringing chimeric antigen receptor T-cell therapy to the ...